Subscribe to RSS
DOI: 10.1055/s-0037-1601757
Antidiabetic sFRP5 is downregulated in patients with chronic periodontitis
Publication History
Publication Date:
05 May 2017 (online)
Introduction:
Diabetes mellitus in humans is known to be associated with periodontitis. Periodontitis is an inflammatory disease affecting 11.2% of the global population and even > 30% germans. Yet, mechanistical links between these two diseases are not fully understood. Here, we investigate the role of diabetes markers and the antidiabetic adipokine secreted frizzled-related protein5 (sFRP5) in chronic progressive periodontitis with tooth loss (PP).
Patients and Methods:
sFRP5 serum levels were obtained in 746 human individuals from the FoCus cohort using ELISA. Additionally, markers for metabolic inflammation (glucose, insulin, triglycerides, IL6, CRP) were measured. N = 128 patients with PP and n = 245 patients with chronic periodontitis without tooth loss were compared to n = 373 sex-, smoker-, age- and BMI-matched controls.
Results:
Serum levels of sFRP5 are significantly lower in patients with PP compared to controls. No association was found for markers of metabolic inflammation (IL6, CRP) in patients with PP compared to controls. But, diabetes mellitus markers (insulin, glucose, triglycerides) were significantly increased in PP patients.
Conclusion:
Low sFRP5 serum levels and high insulin, glucose and triglyceride serum levels might be involved in the pathogenesis of PP; independently, since sFRP5 does not correlate with HOMA-IR in patients with PP. We show that in patients with PP, lower anti-inflammatory adipokine levels can be measured systemically as it can be in diabetes mellitus and distinguish between different stages of periodontitis. Further studies shall reveal the role of sFRP5 in the pathogenesis of PP and show whether recombinant sFRP5 might be a treatment option.